MetaVia (NASDAQ:MTVA) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of MetaVia (NASDAQ:MTVA – Free Report) to a sell rating in a report released on Saturday morning.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $82.50.

Get Our Latest Analysis on MetaVia

MetaVia Trading Down 8.7%

Shares of NASDAQ:MTVA opened at $8.73 on Friday. The stock has a 50 day moving average of $8.90 and a 200 day moving average of $8.73. The company has a market cap of $19.21 million, a PE ratio of -1.04 and a beta of 0.27. MetaVia has a 12-month low of $6.05 and a 12-month high of $30.25.

MetaVia (NASDAQ:MTVA – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($2.86) by $1.32. Equities research analysts predict that MetaVia will post -3.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MetaVia

An institutional investor recently raised its position in MetaVia stock. SG Americas Securities LLC lifted its stake in MetaVia Inc. (NASDAQ:MTVA – Free Report) by 44.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 60,386 shares of the company’s stock after buying an additional 18,506 shares during the quarter. SG Americas Securities LLC owned approximately 0.25% of MetaVia worth $57,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.37% of the company’s stock.

MetaVia Company Profile

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.

Further Reading